Brookstone Capital Management’s UroGen Pharma URGN Stock Holding History

Brookstone Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Buy	+6,000	New	+$163K	﹤0.01%	1221

Other funds holding URGN

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brookstone Capital Management's URGN Position: Q2 2026 in Review

Brookstone Capital Management opened a new position in UroGen Pharma (URGN) in Q2 2026: 6,000 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1221 among its holdings.

15 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Brookstone Capital Management held 6,000 shares of UroGen Pharma worth $221K as of Q2 2026.
UroGen Pharma was a new Brookstone Capital Management position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #1221 holding.
15 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.